The HEMGN Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt expression of the HEMGN gene in the human A-549 cell line. This product employs CRISPR/Cas9-mediated gene disruption to generate a heterogeneous pool of knockout cells, eliminating functional HEMGN protein and enabling loss-of-function studies. The polyclonal format provides a robust, population-level knockout model suitable for a variety of downstream assays without the limitations of single-cell clone artifacts. Researchers can utilize this cell population to interrogate HEMGN-dependent phenotypes in a lung adenocarcinoma background.
The host cell line, A-549, is a well-characterized human non-small cell lung carcinoma model derived from a 58-year-old male patient. It is extensively employed in pharmacological and toxicological research, particularly for studying drug metabolism, cytotoxicity, and cancer biology. As an epithelial cell line, A-549 retains key characteristics of lung adenocarcinoma, making it an appropriate system to explore transcription factor functions in an oncogenic context.
HEMGN encodes a transcriptional regulator predominantly reported in hematopoietic cell development and differentiation. It acts within a multiprotein complex that includes TAL1 and LDB1, and its expression is governed by master hematopoietic transcription factors GATA1 and SPI1, as well as cytokine receptors such as EPOR and IL-3R. Downstream, HEMGN influences the expression of cell cycle regulators like Cyclin D1 and CDK inhibitors, along with apoptotic factors, thereby modulating proliferation and survival programs. Representative pathway components such as GATA1, KLF1, and JAK-STAT signaling mediators further position HEMGN at the intersection of transcriptional and cytokine-responsive networks.
Knockout of HEMGN in the non-hematopoietic A-549 background presents a unique opportunity to dissect its extramedullary functions. Since A-549 cells do not normally participate in hematopoiesis, this model can reveal HEMGN’s potential roles in solid tumor cell proliferation, differentiation, and adaptation to stress. Studies may elucidate whether HEMGN contributes to lung adenocarcinoma pathophysiology, perhaps by modulating downstream targets that govern cell cycle progression or apoptosis. This polyclonal system thus bridges gaps between hematopoietic and cancer transcriptional biology.
Typical research applications include functional genomics approaches such as RNA-seq and RT-qPCR to identify HEMGN target genes and pathways. Cell-based assays??including MTT or CellTiter-Glo viability tests, flow cytometry for cell cycle and apoptosis, colony formation, and migration/invasion assays??are well suited to this model. Moreover, chemosensitivity assays can assess how HEMGN loss modifies drug responses, while co-culture setups can explore tumor-stroma interactions. For further technical assistance, please contact Ascent Research.
